Format

Send to

Choose Destination
Ann Oncol. 2012 Apr;23(4):1023-9. doi: 10.1093/annonc/mdr328. Epub 2011 Jul 21.

Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.

Author information

1
Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA. helen.chew@ucdmc.ucdavis.edu

Abstract

BACKGROUND:

Chemotherapy in combination with small-molecule epidermal growth factor receptor inhibitors has yielded inconsistent results. Based on preclinical models, we conducted a phase I trial of two schedules of lapatinib and vinorelbine.

PATIENT AND METHODS:

Patients had advanced solid tumors and up to two prior chemotherapeutic regimens. Patients were enrolled on two dose-escalating schedules of lapatinib, continuous (arm A) or intermittent (arm B), with vinorelbine on days 1, 8, and 15 of a 28-day cycle. Tumors from a subset of patients were evaluated for gene mutations and expression of targets of interest.

RESULTS:

Fifty-one patients were treated. The most common grade 3/4 toxic effects included leukopenia, neutropenia, and fatigue. Dose-limiting toxic effects were grade 3 infection, febrile neutropenia, and diarrhea (arm A) and bone pain and fatigue (arm B). The maximum tolerated dose was vinorelbine 20 mg/m(2) weekly and lapatinib 1500 mg daily (arm A) and vinorelbine 25 mg/m(2) weekly and lapatinib 1500 mg intermittently (arm B). One patient on each arm had a complete response; both had human epidermal growth factor receptor 2-positive breast cancer. In a subset of patients, lack of tumor PTEN expression correlated with a shorter time to progression.

CONCLUSION:

In an unselected population, two schedules of lapatinib and vinorelbine were feasible and well tolerated.

PMID:
21778300
DOI:
10.1093/annonc/mdr328
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center